Abstract
Fungal infections afflict an increasing number of patients due to increases in susceptible immunosuppressed populations such as those receiving chemotherapy, transplant conditioning or infections such as HIV. Poor responses to available therapy have prompted searches for novel drug targets, but screens can be difficult as expression of these targets often relies on specific inducing conditions present within the mammalian host. Cryptococcus is a yeast-like basidiomycete fungus capable of causing fatal cryptococcocis in both immunocompetent and immunocompromised individuals, and is currently the fourth cause of infectious death in regions of Sub-Sahara Africa, excluding HIV. A key virulence factor of Cryptococcus is a cell-wall laccase, which produces melanin in the presence of exogenous catecholamines. Screening melanin-deficient strains of the fungus is facile and has identified cellular processes critical for virulence including copper homeostasis and autophagy. As demonstrated here through the analysis of laccase regulatory networks of Cryptococcus, genetic analysis targeting virulence-associated regulatory pathways can lead to the discovery of promising novel drug candidates against fungal species.
Keywords: AIDS, biological markers, clinical markers, Cryptococcus, drug design, laccase, regulation, review.
Current Enzyme Inhibition
Title:Laccase Regulators in Anti-fungal Drug Discovery: Dark Lessons from the AIDS-related Pathogen, Cryptococcus
Volume: 9 Issue: 2
Author(s): Jennifer Rabjohns and Peter R. Williamson
Affiliation:
Keywords: AIDS, biological markers, clinical markers, Cryptococcus, drug design, laccase, regulation, review.
Abstract: Fungal infections afflict an increasing number of patients due to increases in susceptible immunosuppressed populations such as those receiving chemotherapy, transplant conditioning or infections such as HIV. Poor responses to available therapy have prompted searches for novel drug targets, but screens can be difficult as expression of these targets often relies on specific inducing conditions present within the mammalian host. Cryptococcus is a yeast-like basidiomycete fungus capable of causing fatal cryptococcocis in both immunocompetent and immunocompromised individuals, and is currently the fourth cause of infectious death in regions of Sub-Sahara Africa, excluding HIV. A key virulence factor of Cryptococcus is a cell-wall laccase, which produces melanin in the presence of exogenous catecholamines. Screening melanin-deficient strains of the fungus is facile and has identified cellular processes critical for virulence including copper homeostasis and autophagy. As demonstrated here through the analysis of laccase regulatory networks of Cryptococcus, genetic analysis targeting virulence-associated regulatory pathways can lead to the discovery of promising novel drug candidates against fungal species.
Export Options
About this article
Cite this article as:
Rabjohns Jennifer and Williamson R. Peter, Laccase Regulators in Anti-fungal Drug Discovery: Dark Lessons from the AIDS-related Pathogen, Cryptococcus, Current Enzyme Inhibition 2013; 9 (2) . https://dx.doi.org/10.2174/1573408011309020006
DOI https://dx.doi.org/10.2174/1573408011309020006 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-cancer Effects of Curcumin on Head and Neck Cancers
Anti-Cancer Agents in Medicinal Chemistry Effect of Non-Steroidal Anti-Inflammatory Drugs on Bone Turnover: An Evidence-Based Review
Reviews on Recent Clinical Trials Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging Molecular Advances Toward the Understanding of the Patho-Biology of Idiopathic Myelofibrosis
Current Immunology Reviews (Discontinued) Simultaneous Interruption of Signal Transduction and Cell Cycle Regulatory Pathways: Implications for New Approaches to the Treatment of Childhood Leukemias
Current Drug Targets Radionuclide Therapy of Cancer with Radiolabeled Antibodies
Anti-Cancer Agents in Medicinal Chemistry What is the Optimal Treatment for Anemia in Inflammatory Bowel Disease?
Current Drug Delivery Agonists of the Tissue-Protective Erythropoietin Receptor in the Treatment of Parkinson’s Disease
Current Topics in Medicinal Chemistry The Prognosis and Treatment of Adult Acute Leukemia with 11q23/MLL According to the Fusion Partner
Current Cancer Therapy Reviews The Role of Pemetrexed in Advanced Non Small-Cell Lung Cancer: Special Focus on Pharmacology and Mechanism of Action
Current Drug Targets Clinical Practice of Umbilical Cord Blood Stem Cells in Transplantation and Regenerative Medicine - Prodigious Promise for Imminent Times
Recent Patents on Biotechnology Genomic Instability and Carcinogenesis: An Update
Current Genomics Intrinsic Properties of Mesemchymal Stem Cells from Human Bone Marrow, Umbilical Cord and Umbilical Cord Blood Comparing the Different Sources of MSC
Current Stem Cell Research & Therapy Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms
Cardiovascular & Hematological Disorders-Drug Targets Targeting the Ubiquitin-Proteasome Pathway in Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design Histone Deacetylase Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Fluoroquinolones Prophylaxis of Bacterial Infections in Neutropenic Patients: Time to Re-Evaluate
Current Cancer Therapy Reviews MicroRNAs in Colorectal Neoplasia: From Pathobiology to Clinical Applications
Current Pharmaceutical Biotechnology Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry